Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta‐analysis

Chronic Diseases and Translational Medicine - Tập 3 - Trang 95-104 - 2017
Song Fan1,2, Zong-Yao Hao1,2, Meng Zhang1,2, Chao-Zhao Liang1,2
1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China
2Institute of Urology, Anhui Medical University, Hefei, Anhui 230032, China

Tóm tắt

AbstractObjectiveThe proposal of the present study was to investigate whether the TP53 rs1042522 polymorphism confers susceptibility to prostate cancer (PCa), by performing an updated meta‐analysis.MethodsEligible publications investigating the association between the TP53 rs1042522 polymorphism and PCa susceptibility were selected from PubMed, Google Scholar, and Web of Science. We used STATA 12.0 software to conduct the analyses. Odds ratio (OR) with 95% confidence interval (CI) was calculated.ResultsA total of 17 case–control studies were retrieved reporting a total of 2683 cases and 2981 controls. However, no significant association was uncovered between the TP53 rs1042522 polymorphism and PCa susceptibility in the overall population under the five genetic models. In the stratification analysis by source of control, an increased susceptibility to PCa was identified in the population‐based (P‐B) group (CG vs. GG: OR = 1.48, 95% CI: 1.24–1.77, P < 0.01; CC/CG vs. GG: OR = 1.32, 95% CI: 1.12–1.57, P < 0.01), whereas a decreased susceptibility was uncovered in the hospital‐based (H‐B) group (CG vs. GG: OR = 0.67, 95% CI: 0.46–0.96, P = 0.03; CC/CG vs. GG: OR = 0.67, 95% CI: 0.46–0.99, P = 0.04) under heterozygous and dominant model.ConclusionThis study did not find an association between the TP53 rs1042522 polymorphism and PCa susceptibility in the overall population and corresponding subgroup analyses except in the stratification analysis by source of control. The results suggest that the TP53 rs1042522 polymorphism is not a risk factor for PCa.

Tài liệu tham khảo

10.3322/caac.21254 10.1038/nrurol.2013.266 10.1038/ng.2560 10.1038/ng.610 10.1002/ijc.24611 10.1093/nar/18.16.4961 10.7314/APJCP.2014.15.9.3973 10.1007/s12032-009-9245-5 10.1016/0197-2456(86)90046-2 10.1136/jech.53.9.583 10.1136/bmj.315.7109.629 10.2307/2533446 10.1002/pros.10021 10.1007/BF02256434 10.1158/1055-9965.2217.13.12 10.1159/000078803 10.1186/1471-2490-5-15 10.1111/j.1745-7262.2006.00135.x 10.1158/1078-0432.CCR-07-0859 10.1016/j.juro.2008.11.093 10.1016/j.cancergencyto.2010.02.014 10.1002/pros.21209 10.1016/j.arcmed.2011.03.001 Doosti A., 2011, The p53 codon 72 polymorphism and association to prostate cancer in Iranian patients, Afr J Biotechnol, 10, 12821, 10.5897/AJB11.1442 10.1159/000326767 Bansal A., 2012, Implication of DNA repair genes in prostate tumourigenesis in Indian males, Indian J Med Res, 136, 622 10.1002/jmv.23268 10.1016/j.urolonc.2010.09.011 10.1126/science.1905840 10.1093/jnci/85.20.1657 10.1111/j.1601-0825.2010.01664.x 10.1089/dna.2009.0995 10.1186/1471-2407-10-88 10.1016/j.cancergencyto.2009.09.013 10.4103/0019-509X.58856 10.1007/s12032-009-9297-6 10.1128/MCB.19.2.1092 10.1007/s13277-014-1657-y 10.4238/2011.November.29.3
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 3

95-104

Thông tin tác giả